The Corona Remedies IPO will open for subscription on December 8, 2025, and close on December 10, 2025. This is a Book Built Issue through which the company aims to raise around ₹655.37 crores. The offer includes a fresh issue of ₹[.] crores along with an offer for sale of up to 61,71,101 equity shares of face value ₹10 each.
The IPO price band has been set between ₹1008 and ₹1062 per share. The investor quota is divided as 50% for QIBs, 15% for NIIs/HNIs, and 35% for retail investors. The allotment will be announced on December 11, 2025, followed by listing on both BSE and NSE on December 15, 2025.
The company posted strong revenue of ₹1,202.35 crores in FY2025 against ₹1,020.93 crores in FY2024. Profit also improved to ₹149.43 crores in FY2025 from ₹90.50 crores in FY2024. Based on its financial growth and strong presence in the pharmaceutical market, long-term investors may consider applying.
Contents
Corona Remedies IPO Details
| Particular | Details |
|---|---|
| IPO Open Date | December 8, 2025 |
| IPO Close Date | December 10, 2025 |
| Face Value | ₹10 per equity share |
| IPO Price Band | ₹1008 to ₹1062 per share |
| Issue Size | Approx ₹655.37 crores |
| Offer for Sale | Approx 61,71,101 equity shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE, NSE |
| DRHP | View PDF |
| RHP | View PDF |
Corona Remedies IPO
Open: 8-10 Dec
Issue Size: ₹ 655.37 Cr.
Objective: Allow existing investors, promoters to exit via a sale of shares on stock markets.
Exchange: BSE NSE
Corona Remedies IPO GMP Today
Corona Remedies IPO continues to attract strong interest in the grey market, with the latest GMP holding firm at ₹365 as of 5th December 2025.
With a price band of ₹1062, the IPO’s estimated listing price stands at ₹1427, indicating an impressive 34.37% listing gain if sentiments remain steady. Retail Subject to Sauda is quoted at ₹3900, while Small HNI quotes have touched ₹54,600, reflecting robust demand across categories.
The GMP trend over the past four sessions shows a clear upward movement, suggesting strong listing expectations. The premium moved from ₹307 on 3rd December to ₹365, and has remained stable. The table below highlights the day-wise momentum and expected profit:
| Date | GMP | Sub2 Sauda | Est. Listing Price | Est. Profit |
|---|---|---|---|---|
| 05-12-2025 | ₹365 | 3900 / 54600 | ₹1427 (34.37%) | ₹5110 |
| 04-12-2025 | ₹365 | 3900 / 54600 | ₹1427 (34.37%) | ₹5110 |
| 03-12-2025 | ₹307 | 3300 / 46200 | ₹1369 (28.91%) | ₹4298 |
| 02-12-2025 | ₹0 | — | — | — |
These numbers are purely indicative of grey market sentiment. They should not be treated as investment advice or a trading recommendation.
Corona Remedies IPO Review
Corona Remedies is a well-established name in the pharma industry with strong revenue growth, robust profitability, and significant market presence.
The brand operates across multiple therapeutic areas and has an expanding distribution network. Considering the financials and valuation metrics, the IPO may be suitable for investors with a medium-to-long-term horizon.
Corona Remedies IPO Market Lot
The minimum lot size for retail investors is 14 shares. One retail lot will cost ₹14,868. The maximum retail application allowed is 13 lots.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 14 | ₹14,868 |
| Retail Maximum | 13 | 182 | ₹1,93,284 |
| S-HNI Minimum | 14 | 196 | ₹2,08,152 |
| S-HNI Maximum | 67 | 938 | ₹9,96,156 |
| B-HNI Minimum | 68 | 952 | ₹10,11,024 |
- Also Read: Flywings Simulator IPO
IPO Reservation
| Investor Category | Shares Offered | % Shares |
|---|---|---|
| Anchor Investor | – Shares | –% |
| QIB (Ex-Anchor) | – Shares | 50% |
| NII | – Shares | 15% |
| Retail | – Shares | 35% |
Corona Remedies IPO Anchor Investor
| Particular | Details |
|---|---|
| Anchor Bidding Date | December 5, 2025 |
| Anchor Investors List | View PDF |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| Lock-in 50% (30 days) | January 10, 2026 |
| Lock-in 50% (90 days) | March 11, 2026 |
Corona Remedies IPO Timeline
| Event | Date |
|---|---|
| IPO Open Date | December 8, 2025 |
| IPO Close Date | December 10, 2025 |
| Basis of Allotment | December 11, 2025 |
| Refunds | December 12, 2025 |
| Credit to Demat | December 12, 2025 |
| Listing Date | December 15, 2025 |
| Cut-off Time | December 10, 2025 – 5 PM |
Promoters and Shareholding
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 6,11,60,088 | 72.50% |
| Promoter Holding Post Issue | 6,11,60,088 | –% |
Promoters:
Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, and Ankur Kirtikumar Mehta.
Objects of the Issue
The proceeds from the fresh issue will be utilised for business expansion, strengthening working capital, improving manufacturing capabilities, and general corporate purposes.
The company aims to enhance its presence across existing therapeutic segments and support future growth initiatives.
About Corona Remedies
Founded in August 2004, Corona Remedies Limited is a leading pharmaceutical company engaged in manufacturing and marketing products related to women’s health, cardiology, diabetes, urology, pain management, and multispecialty segments. It holds the 2nd largest position in the Indian Pharmaceutical Market among 30 competitors.
As of December 31, 2024, the company has 88 R&D professionals, a wide portfolio of 67 brands, and operates across 22 states through 2,598 medical representatives. It runs two manufacturing facilities in Gujarat.
Corona Remedies Financial Performance
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2023 | ₹891.10 Cr | ₹756.07 Cr | ₹84.93 Cr | ₹595.02 Cr |
| 2024 | ₹1,020.93 Cr | ₹859.74 Cr | ₹90.50 Cr | ₹830.58 Cr |
| 2025 | ₹1,202.35 Cr | ₹956.44 Cr | ₹149.43 Cr | ₹929.86 Cr |
| June 2025 | ₹348.56 Cr | ₹276.76 Cr | ₹46.20 Cr | ₹1,012.38 Cr |
Corona Remedies IPO Valuation – FY2025
| KPI | Values |
|---|---|
| ROE | 27.50% |
| ROCE | 41.32% |
| EBITDA Margin | 20.55% |
| PAT Margin | 12.49% |
| Debt to Equity | – |
| EPS (Basic) | ₹24.43 |
| P/E Ratio | N/A |
| RoNW | 24.65% |
| NAV | ₹99.14 |
Peer Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Abbott India | 665.62 | 54.28 | 33.41% | 1,992.14 | 6,409.15 Cr |
| Alkem Laboratories | 181.11 | 32.96 | 18.07% | 1,002.37 | 12,964.52 Cr |
| Eris Lifesciences | 25.85 | 47.99 | 12.21% | 209.73 | 2,893.64 Cr |
| GSK Pharma | 54.76 | 83.53 | 47.54% | 115.19 | 3,749.21 Cr |
| J.B. Chemicals | 42.45 | 47.21 | 19.21% | 220.88 | 3,917.99 Cr |
| Mankind Pharma | 49.28 | 54.17 | 13.89% | 352.51 | 12,207.44 Cr |
| Pfizer | 167.79 | 34.56 | 18.20% | 921.88 | 2,281.35 Cr |
| Sanofi India | 179.46 | 23.76 | 48.05% | 373.68 | 2,013.20 Cr |
| Torrent Pharma | 56.47 | 66.51 | 25.18% | 224.28 | 11,516.09 Cr |
IPO Lead Managers
- JM Financial Ltd.
- IIFL Capital Services Ltd.
- Kotak Mahindra Capital Co. Ltd.
Company Address
| Particular | Details |
|---|---|
| Company Name | Corona Remedies Ltd. |
| Address | CORONA House, C – Mondeal Business Park, Near Gurudwara S.G. Highway, Thaltej, Ahmedabad, Gujarat – 380059 |
| Phone | +91 79 4023 3000 |
| complianceofficer@coronaremedies.com | |
| Website | https://www.coronaremedies.com/ |
IPO Registrar
| Particular | Details |
|---|---|
| Registrar | Bigshare Services Pvt. Ltd. |
| Phone | +91-22-6263 8200 |
| ipo@bigshareonline.com | |
| Website | https://ipo.bigshareonline.com/IPO_Status.html |
Corona Remedies IPO FAQs
What is the Corona Remedies IPO?
It is a Mainboard IPO through which the company plans to raise ₹655.37 crores. The price band is ₹1008–₹1062 per share, and the stock will list on BSE and NSE.
When will the IPO open?
The IPO opens on December 8, 2025, and closes on December 10, 2025.
What is the investor quota?
QIBs get 50%, NIIs 15%, and retail investors 35%.
How can I apply for this IPO?
You can apply online via ASBA through your bank or apply using UPI through your stockbroker. Offline applications via brokers are also accepted.
What is the issue size?
The total issue size is ₹655.37 crores.
What is the lot size?
Retail investors must apply for a minimum of 14 shares.
When is the allotment date?
The allotment will be announced on December 11, 2025.
When is the listing date?
Listing is scheduled for December 15, 2025.
Expert Comment
Corona Remedies shows consistent revenue and profit growth along with a strong presence in high-potential therapeutic segments. The company’s financial discipline, expanding product portfolio, and R&D-driven strategies make it a promising long-term contender.
Although the valuation appears on the higher side, the fundamentals are strong enough to draw interest from informed investors. Those looking for stability and sector leadership may find this IPO worthwhile for long-term holding.
